Prescient Therapeutics (ASX: PTX) - Groundbreaking...
In this exclusive interview, Jess Fertig hosts James McDonnell, CEO of Prescient Therapeutics (ASX: PTX), a biotech innovator in the healthcare sector. Discover how PTX's lead asset, PTX 100, is advancing through crucial Phase 2 trials targeting cutaneous T cell lymphoma (CTCL), with promising response rates and minimal serious adverse events. James shares insights into the company's strategic pathway, including FDA fast track designation and potential market opportunities exceeding $1.8 billion
en-au